Send us a text

Every life-saving drug we know of—every cancer therapy, every vaccine, every breakthrough—started as an impossible idea. Turning that idea into reality takes more than science. It takes persistence, investment, and a patent system strong enough to protect innovation. In this episode of IPWatchdog Unleashed, Gene Quinn (IPWatchdog) sits down with Rob Sahr, a Shareholder at Wolf Greenfield, to unpack the extraordinary journey from molecule to medicine. Together, they explore how scientific breakthroughs depend not only on research and capital, but also on a stable and predictable patent system. From double patenting and government funding to judicial uncertainty and policy headwinds, the conversation dives into the fragile balance between innovation and access—and the miracles required to bring new drugs to life.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.